North America Viral Vector and Plasmid DNA Manufacturing Market Trends Growth Forecast Research Report 2022 | DataM Intelligence

North America Viral Vector and Plasmid DNA Manufacturing Market | DataM Intelligence
North American viral vector and plasmid DNA manufacturing market is segmented into major countries including the US, Canada, and Mexico. In the North American region, the United States holds the dominant share of about 71% in 2020, followed by Canada. The United States is the most lucrative market for viral vector and plasmid DNA manufacturing.

Market Overview:

A vector is a tool for delivering genetic material into cells. The modified viral vector is used as the viral vector in gene therapy. Plasmid D viralNA is a bacterial smaller, circular and extrachromosomal DNA used in different molecular genetic research such as gene therapy, gene transfer, and recombinant DNA technology due to its self-replication property. A gene of interest is transferred into the target cell for studying the function or expression of a gene.

Market Size Growth Rate:

According to the research report published by the DataM Intelligence, the North America viral vector and plasmid DNA manufacturing market size was valued at USD billion in 2021, it is projected to reach USD billion by 2029, with growth at a CAGR over the forecast period 2022-2029.

There is an increasing number of clinical studies conducted on viral vector manufacturing, emphasizing the potential of gene therapy to address important medical needs. Major pharmaceutical companies such as AstraZeneca, and Janssen Pharmaceuticals have developed COVID-19 viral vector-based vaccines in December 2020 and February 2021, respectively. Apart from these companies, several viral vector-based vaccines are currently in the development phase. This has accelerated the demand for viral vectors, thereby increasing revenue for viral vector manufacturers.

Market Drivers:

The market is driven by the increasing demand for viral vectors and plasmid DNA manufacturing for developing DNA vaccines, gene therapy, immunotherapy, and others. There is growing usage of the viral vectors & plasmid DNA due to their advantages such as high transfection efficiency, effective gene delivery, and stable gene expression. There is a rise in the number of clinical studies for examining the efficacy and safety of the viral vectors. In addition, increase in the launch of the contract manufacturing business for viral vectors and plasmid DNA manufacturing. For instance, in December 2019, Helixmith Co., Ltd. and Genopis launched the contract manufacturing business for plasmid DNA production.

Market Restraints:

However, some of the limitations of gene therapy is likely to hamper the market growth. In addition, risk associated with viral vectors, complex and expensive manufacturing processes, and regulatory challenges are some of the restraints to the market growth.

Market Opportunities

The success of any viral-vector manufacturing market depends on its ability to get past multiple lines of defense deployed by the human immune system. Viral capsids, viral-vector DNA, and even the transgene products themselves may be recognized as foreign, providing multiple opportunities for the immune system to clear the gene therapy from the body. In addition, the COVID-19 pandemic and the R&D for vaccines have created serval opportunities for the market.

COVID-19 Impact Analysis

The COVID-19 pandemic has underlined the importance of vaccine development for the global population. According to the World Health Organization (WHO), around 151 vaccine candidates have been subjected to preclinical studies and 42 vaccines have reached clinical trials. Viral vectors have played a central role, especially using adenovirus-based vectors. Additionally, other viral vectors based on vaccinia viruses, measles viruses, rhabdoviruses, influenza viruses, and lentiviruses have been subjected to vaccine development. Increasing research involving viral vectors is expected to continue at least for the next one or two years. This is expected to boost the market growth.

Download Sample Brochure @

Recent Developments in the Industry:

In December 2020, CHA Biotech signed a lease agreement with Matica Bio to construct a viral vector production facility in College Station, Texas.
In April 2020, Merck boosts commercial viral vector and gene therapy manufacturing capacity, with a second Carlsbad, California, USA-based facility for its BioReliance viral and gene therapy service offering.
in May 2020, Thermo Fisher Scientific Inc. expanded its capacity for viral vector development and manufacturing services with the construction of a new commercial manufacturing site in Plainville, Mass.
In October 2019, SIRION Biotech expanded into the U.S. viral vector market by opening a new office in Massachusetts.

Market Segmentation:

As per the research analysis, the viral vector and plasmid DNA manufacturing market is segmented by type into retroviral vectors, adenoviral vectors, lentiviral vectors, adeno-associated viral vectors, and others. Based on disease, the market is segmented into cancer, genetic disorder, infectious disease, and other diseases. Further, by application, it is further divided into gene therapy, and vaccinology, and by end-user, it is segmented into pharmaceutical and biopharmaceutical companies, and research institutes.

By type of vectors, the adenoviral vectors segment is estimated to account for a share of around 29% of the viral vector manufacturing market by 2020. Adenoviral vectors are the most commonly employed vector for cancer gene therapy. They are also used for gene therapy and as vaccines to express foreign antigens.
Based on the type of disease, the cancer segment accounted for the largest market share, owing to the high prevalence of cancer and increased acceptance of gene therapy for the treatment of cancer. Gene therapy involves the transfer of genetic information to a target cell to facilitate the production of therapeutic proteins and is now a realistic prospect as a cancer treatment. Multiple gene therapy strategies have been developed to treat a wide variety of cancers, including gene therapy with suicide genes, oncolytic viruses, anti-angiogenic genes, and therapeutic gene vaccines.

Geographical Classification:

The North American viral vector and plasmid DNA manufacturing market is segmented into major countries including the US, Canada, and Mexico.

US Viral Vector And Plasmid DNA Manufacturing Market:

In the North American region, the United States holds the dominant share of about 71% in 2020, followed by Canada. The United States is the most lucrative market for viral vector and plasmid DNA manufacturing. The growth in the region is due to the presence of several biopharmaceutical manufacturers in the U.S., coupled with advanced funding and public awareness. The Alliance for Regenerative Medicine (ARM), a U.S.-based non-profit organization in the field of gene therapy, reported a 164% increase in funding for gene and gene-modified cell therapy in 2017 over 2016 and a global investment of USD 4.5 billion in 2017. In November 2018, the National Institutes of Health (NIH) launched a new initiative to accelerate the adoption of gene therapy to cure around 20 million patients diagnosed with sickle cell disease.

Competitive Analysis:

Companies involved in the development of vector agent-based products often seek support from contract service providers for the launch of clinical-grade products. This is primarily because of the complexity and limited availability of technologies and platforms used for vector designing, production, packaging, and release testing. The major players are entering into collaborations, acquisitions, mergers, and licensing activities for increasing their market presence. For instance, in January 2021, Thermo Fisher Scientific acquired the viral-vector manufacturing business of the French pharmaceutical services firm Novasep for approximately $875 million.

Make an inquiry to purchase the complete study @

Major Companies:

Lonza, Merck, Oxford BioMedica, CGT Catapult, Cobra Biologics, UniQure, Sanofi, FUJIFILM Diosynth Biotechnologies, Cobra Biologics, Thermo Fisher Scientific, Inc., and Spark Therapeutics are some of the major key players in the market.

Additional Benefits Post Purchase:

1) Unlimited Analyst support for a period of 1 year.

2) Any query with regards to the scope offered will be addressed within 24- 48 hours.

3) An excel sheet with market numbers will be provided separately.

The Full Report has the below insights:

The report offers a comprehensive evaluation of the market in terms of Market Value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2020-2021), and verifiable projections about market size during the forecast period (2022-2029).
Visualize the composition of the North American viral vector and plasmid DNA manufacturing market segmentation by type, disease, application, end-user, and country highlighting the key commercial assets and players.
By Type: Retroviral Vectors, Adenoviral Vectors, Lentiviral Vectors, Adeno-associated Viral Vectors, Others
By Disease: Cancer, Genetic Disorder, Infectious Disease, Other diseases
By Application: Gene Therapy, Vaccinology
By End User: Pharmaceutical and Biopharmaceutical Companies, Research Institutes
By Country: US, Canada, Mexico
Identify commercial opportunities in the North America viral vector and plasmid DNA manufacturing market by analyzing trends and co-development deals.
The report also covers data insights on various industry forces such as, porter’s five forces, regulations in each country, supply chain, pipeline analysis, and epidemiology.
Excel data sheet with thousands of data points of North America viral vector and plasmid DNA manufacturing market-level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study. 
Product mapping in excel for the key product of all major market players
The report will provide access to approximately 50+ market data tables, 40+ figures, and close to 180 pages.  

Media Contact
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States

Are you a market researcher?

Explore our research partnership options.


Find out what people like and dislike about your competitors, and compare it with your brand performance.

Competitor Analyzer

Generated by Feedzy
%d bloggers like this: